Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation

Blood blood.2024025563.

https://doi.org/10.1182/blood.2024025563

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic Understanding in Newly Diagnosed Older Adults with Diffuse Large B Cell Lymphoma (DLBCL) or DLBCL/High Grade B-Cell Lymphoma with MYC and BCL2 rearrangements

Netana Markovitz, Oreofe O. Odejide, Areej El-Jawahri, Patrick Connor Johnson

Blood (2023) 142 (Supplement 1): 2409.

https://doi.org/10.1182/blood-2023-187708

Published: 2023

Journal Articles

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 738.

https://doi.org/10.1182/blood-2023-180069

Published: 2023

Journal Articles

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Blood (2023) 142 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2023-184345

Published: 2023

Journal Articles

Pilot Randomized Controlled Trial of an Educational Video for Chimeric Antigen Receptor (CAR)-T Cell Therapy Recipients

Patrick Connor Johnson, Tejaswini Dhawale, Richard Newcomb, Anna Barata, Kyle Karpinski, Mitchell Lavoie, Dagny Vaughn, Kathleen Hennessey, David Scheider, Hermioni L Amonoo, Angelo Volandes, Areej El-Jawahri

Blood (2023) 142 (Supplement 1): 255.

https://doi.org/10.1182/blood-2023-172776

Published: 2023

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Journal Articles

Longitudinal Patient-Reported Outcomes and Clinical Outcomes By VES-13 and Comprehensive Geriatric Assessment in Older Adults with Aggressive Non-Hodgkin Lymphomas

Patrick Connor Johnson, Netana Markovitz, Richard Newcomb, Daniel Yang, Julia Rice, Bridget Coffey, Oreofe O. Odejide, Areej El-Jawahri

Blood (2023) 142 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2023-187346

Published: 2023

Journal Articles

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells

Philipp Karschnia, Kevin C. Miller, Andrew J. Yee, Kai Rejeski, P. Connor Johnson, Noopur Raje, Matthew J. Frigault, Jorg Dietrich

Blood (2023) 142 (14): 1243–1248.

https://doi.org/10.1182/blood.2023020571

Published: 2023

Journal Articles

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Blood (2022) 140 (Supplement 1): 1530–1533.

https://doi.org/10.1182/blood-2022-160335

Published: 2022

Journal Articles

Longitudinal Patient-Reported Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Patrick Connor Johnson, Tejaswini Dhawale, Mitchell W. Lavoie, Kyle Karpinski, Netana H. Markovitz, Kathleen Hennessey, Matthew Frigault, Areej El-Jawahri

Blood (2022) 140 (Supplement 1): 5232–5233.

https://doi.org/10.1182/blood-2022-163194

Published: 2022

Journal Articles

Delirium and Healthcare Utilization in Patients Undergoing Hematopoietic Stem Cell Transplantation

Netana H. Markovitz, Areej El-Jawahri, Ciara Dale, Patrick Connor Johnson, Kofi Boateng, Daniel Yang, Hermioni L. Amonoo

Blood (2022) 140 (Supplement 1): 8137.

https://doi.org/10.1182/blood-2022-167964

Published: 2022

Journal Articles

KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 2253–2255.

https://doi.org/10.1182/blood-2022-162583

Published: 2022

Journal Articles

Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Tejaswini Dhawale, P. Connor Johnson, Mahmoud R. Gaballa, Ashley Nelson, Mitchell W. Lavoie, Matthew Frigault, Kofi Boateng, Claire Greydanus, Areej El-Jawahri

Blood (2022) 140 (Supplement 1): 10989–10990.

https://doi.org/10.1182/blood-2022-162494

Published: 2022

Journal Articles

Characteristics of Lymphoma Patients Experiencing Unplanned Readmissions at a Large Academic Medical Center

Uvette Lou, Matthew M Lei, Mark Sorial, Daniel Lage, Kenechukwu Aniagboso, Emily Buttermore, Margaret Soriano, Ryan D. Nipp, Patrick Connor Johnson

Blood (2022) 140 (Supplement 1): 13088–13089.

https://doi.org/10.1182/blood-2022-168129

Published: 2022

Journal Articles

Treatment Preferences Among Patients with Diffuse Large B-Cell Lymphoma: A Survey across Western Europe and the United States of America

Patrick Connor Johnson, Ruben G.W Quek, Abigail Bailey, Neil Milloy, Isaac Sanderson, Qiufei Ma

Blood (2021) 138 (Supplement 1): 4565.

https://doi.org/10.1182/blood-2021-148459

Published: 2021

Journal Articles

End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma

Netana H. Markovitz, Alisha Yi, Oreofe O. Odejide, Richard Newcomb, Hermioni L. Amonoo, Ashley M. Nelson, Matthew J. Reynolds, Julia Rice, Mitchell W. Lavoie, Ryan D. Nipp, Areej El-Jawahri, Patrick Connor Connor Johnson

Blood (2021) 138 (Supplement 1): 5005.

https://doi.org/10.1182/blood-2021-146527

Published: 2021

Journal Articles

Association of Bridging Therapy Utilization with Clinical Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

P. Connor Johnson, Caron Jacobson, Alisha Yi, Areej El-Jawahri, Matthew J. Frigault

Blood (2021) 138 (Supplement 1): 4100.

https://doi.org/10.1182/blood-2021-152479

Published: 2021

Journal Articles

Real-World Health-Related Quality of Life in Patients with Diffuse Large B-Cell Lymphoma: Comparisons with Reference Populations and By Line of Therapy

Qiufei Ma, Abigail Bailey, Neil Milloy, Jake Butcher, Ruben G.W Quek, Patrick Connor Johnson

Blood (2021) 138 (Supplement 1): 4111.

https://doi.org/10.1182/blood-2021-152798

Published: 2021

Journal Articles

The Associations between Coping Strategy Use and Patient-Reported Outcomes in Patients with Acute Myeloid Leukemia

Matthew J. Reynolds, Monica Bodd, Ashley Nelson, Richard Newcomb, P. Connor Johnson, Tejaswini Dhawale, Lauren Heuer, Sabah Gillani, Daniel Yang, Emma C. Deary, Elizabeth Daskalakis, Lauren Goldschen, Andrew M. Brunner, Amir T. Fathi, Thomas W. LeBlanc, Areej El-Jawahri, Hermioni L. Amonoo

Blood (2021) 138 (Supplement 1): 4131.

https://doi.org/10.1182/blood-2021-151895

Published: 2021

Journal Articles

Hospitalizations and Emergency Department (ED) Visits after CAR-T Therapy - Real World Experience in Commercially Insured Patients

Kelly Kenzik, P. Connor Johnson, Smita Bhatia

Blood (2021) 138 (Supplement 1): 569.

https://doi.org/10.1182/blood-2021-145112

Published: 2021

NARROW

Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation

Prognostic Understanding in Newly Diagnosed Older Adults with Diffuse Large B Cell Lymphoma (DLBCL) or DLBCL/High Grade B-Cell Lymphoma with MYC and BCL2 rearrangements

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Pilot Randomized Controlled Trial of an Educational Video for Chimeric Antigen Receptor (CAR)-T Cell Therapy Recipients

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Longitudinal Patient-Reported Outcomes and Clinical Outcomes By VES-13 and Comprehensive Geriatric Assessment in Older Adults with Aggressive Non-Hodgkin Lymphomas

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Longitudinal Patient-Reported Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Delirium and Healthcare Utilization in Patients Undergoing Hematopoietic Stem Cell Transplantation

KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Characteristics of Lymphoma Patients Experiencing Unplanned Readmissions at a Large Academic Medical Center

Treatment Preferences Among Patients with Diffuse Large B-Cell Lymphoma: A Survey across Western Europe and the United States of America

End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma

Association of Bridging Therapy Utilization with Clinical Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Real-World Health-Related Quality of Life in Patients with Diffuse Large B-Cell Lymphoma: Comparisons with Reference Populations and By Line of Therapy

The Associations between Coping Strategy Use and Patient-Reported Outcomes in Patients with Acute Myeloid Leukemia

Hospitalizations and Emergency Department (ED) Visits after CAR-T Therapy - Real World Experience in Commercially Insured Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only